EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies

Eleonora Dileo iD, Francesca Saba iD, Mirko Parasiliti-Caprino iD, Chiara Rosso iD, Elisabetta Bugianesi iD

Nutrients · 28.01.2025 · 17 (3) · 477

DOI: 10.3390/nu17030477 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 28.01.2025. Verfasst von Eleonora Dileo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, 10126 Turin, Italy. Hauptthemen laut MEDLINE: Sex Characteristics, Fatty Liver, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON-HLTH-2023-ENVHLTH-02 program, project EDC-MASLD, HORIZON-HLTH-2023-ENVHLTH-02 program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum of liver disease ranging from hepatic fat accumulation to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH), fibrosis, cirrhosis, and potentially hepatocellular carcinoma in the absence of excessive alcohol consumption. MASLD is characterized by substantial inter-individual variability in terms of severity and rate of progression, with a prevalence that is generally higher in men than in women. Steroids metabolism is characterized by sexual dimorphism and may have an impact on liver disease progression; indeed, several therapeutic strategies targeting hormone receptors are under phase 2/3 development. Despite the fact that the importance of sexual dimorphism in the setting of MASLD is well recognized, the underlying molecular mechanisms that can potentially drive the disease toward progression are not clear. The aim of this review is to delve into the crosstalk between sexual dimorphism and steroid hormone perturbation under nutritional and pharmacological intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sex CharacteristicsFatty LiverNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumansFemaleMaleSex FactorsDisease Progression

Stichwörter der Autor:innen

metabolic dysfunction-associated steatohepatitismetabolic dysfunction-associated steatotic liver diseasesex hormonessexual dimorphismsteroidstherapy

Autor:innen und Institutionen

  • Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

ORCID-Profile: Eleonora Dileo, Francesca Saba, Mirko Parasiliti-Caprino, Chiara Rosso, Elisabetta Bugianesi

Förderung

  • HORIZON-HLTH-2023-ENVHLTH-02 program, project EDC-MASLD
  • HORIZON-HLTH-2023-ENVHLTH-02 program

Zitieren

APA

Dileo, E., Saba, F., Parasiliti-Caprino, M., Rosso, C., & Bugianesi, E. (2025). Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies. Nutrients, 17(3), 477. https://doi.org/10.3390/nu17030477

Vancouver

Dileo E, Saba F, Parasiliti-Caprino M, Rosso C, Bugianesi E. Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies. Nutrients. 2025;17(3):477. doi:10.3390/nu17030477

BibTeX
@article{Dileo2025,
  author = {Dileo, Eleonora and Saba, Francesca and Parasiliti-Caprino, Mirko and Rosso, Chiara and Bugianesi, Elisabetta},
  title = {Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies},
  journal = {Nutrients},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {477},
  doi = {10.3390/nu17030477}
}
Kostenlos starten →